Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
  • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
  • C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/30—Oestrogens
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
  • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
  • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
  • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J75/00—Processes for the preparation of steroids in general
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• - cyclic ketal such as -O- (CH 2) m -0-, -0- (CH 2) m -S-, -S- (CH 2) m -S-, -0-CH 2 -C ( c 1 _ 4 -alkyl) 2 -CH 2 -0-,
• K is a cyclic ketal and, in particular a 3, 3-ethylenedioxy group.
• this silylation reaction is generally carried out in the presence of a strong base such as Li-HMDS ((Me 3 Si) 2 N- Li), LDA ((iPr) 2 N-Li ), a tertiary amine such as TEA (triethylamine), Na-naphthalene, pyridine and its derivatives such as DMAP (Dimethylaminopyridine), urea, DBU, imidazole, potassium hydride, sodium hydride, n-BuLi, tBuOK or even t-AmONa, DBN and others.
• a strong base such as Li-HMDS ((Me 3 Si) 2 N- Li), LDA ((iPr) 2 N-Li ), a tertiary amine such as TEA (triethylamine), Na-naphthalene, pyridine and its derivatives such as DMAP (Dimethylaminopyridine), urea, DBU, imidazole, potassium hydride
• the silylation reaction is generally carried out in two stages: 1) enolization of the compounds of formula (II) in the presence of a strong base such as LDA in order to obtain the corresponding enolate of formula (II 1 ):
• This arylation will preferably be carried out with an organometallic derivative RsMgBr in THF alone or as a mixture (eg hexane, toluene, dichloromethane) in the presence of cuprous chloride (CuCl) or other copper salts (I) or (II) (such as: CuOAc, CuBr, Cu (OAc) 2 , CuCl 2 ) to form the cuprate intermediate.
• cuprous chloride CuCl
• other copper salts I
• III such as: CuOAc, CuBr, Cu (OAc) 2 , CuCl 2
• the corresponding halogen is carried out in an aprotic medium in an oxygenated solvent such as ether or THF.
• the norsteroid aromatization reaction is a conventional reaction which is carried out in particular according to the methods described in EP 298,020.
• This aromatization can be carried out by catalysis with palladium or preferably in the presence of acetyl bromide and acetic anhydride.
• the deprotection of the acetyl group in 3 formed is generally carried out in the presence of sodium hydroxide in methanol.
• a more particular subject of the invention is a process as defined above, characterized in that the silylated derivative is a trimethylsilyl derivative which makes it possible to obtain a silylated enol of formula (II) in which Ra, Rb and Rc each represent methyl.
• the invention particularly relates to a process as defined above, characterized in that the silylated derivative is ClSiMe 3 .
• the invention particularly relates to a process as defined above, characterized in that the silylation reaction is carried out in the presence of LDA or Li-HMDS.
• the subject of the invention is more particularly a process as defined above, characterized in that an organometallic derivative of formula R 5 -MgBr is used.
• a very particular subject of the invention is a process as defined above, characterized in that an organometallic derivative of formula R 5 -MgBr is used in which:
• a more particular subject of the invention is a process as defined above, characterized in that the deprotective agent used on the compound of formula (III 1 ) to obtain the compound of formula (IV) is an agent allowing acid hydrolysis and in particular hydrochloric acid.
• the invention more particularly relates to a process as defined above, characterized in that the flavoring agent is acetyl bromide in the presence of acetic anhydride.
• the invention particularly relates to a process as defined above, characterized in that a compound of formula (II) is treated with ClSiMe 3 in the presence of a base in order to obtain the silylated enol of formula ( Illa):
• Ri and R 2 which are identical or different, represent a linear or branched alkyl radical containing from 1 to 4 carbon atoms
• organometallic alkylating agent of type R 4 M R 4 being an alkyl radical containing from 1 to 4 carbon atoms unsubstituted or substituted by one or more halogen atoms and M representing Mg-Hal or Li .
• the invention more particularly relates to a process as defined above characterized in that Ri and R 2 represent an alkyl radical containing 1 to 4 carbon atoms or form together with the nitrogen atom which wear a saturated heterocycle chosen from
• n is an integer equal to 2 to 5 and R 3 is a hydrogen atom
• the invention particularly relates to a process as defined above, characterized in that the reducing agent is NaBH 4 .
• a subject of the invention is therefore also the compounds of formulas (I) and (Ib), as defined above as medicaments, in particular for the prevention or treatment of osteoporosis, as well as the pharmaceutical compositions containing at least a medicament as defined above and a pharmaceutically acceptable vehicle.
• the subject of the invention is also a process as defined above, characterized in that the compound of formula (I) is used as an intermediate product for the preparation of a derivative having an estrogenic activity of formula (Ie):
• the invention more particularly relates to a process as defined above characterized in that Ri and R represent an alkyl radical containing 1 to 4 carbon atoms or form together with the nitrogen atom which carry them a saturated heterocycle chosen from
• n is an integer equal to 2 to 5 and R 3 is a hydrogen atom and X is a chlorine atom.
• the invention particularly relates to a process as defined above, characterized in that the halogenating agent, making it possible to introduce the halogen in position 4 of the steroid is N-chlorosuccinimide or N-bromosuccinimide, chlorine or bromine in an acid medium and the reducing agent is sodium borohydride.
• the halogenation reaction takes place before the reduction.
• the invention also relates to a process for the preparation of the compounds of formula (III) from the compounds of formula (II) according to the method as defined above.
• the invention also relates to a process for preparing the compounds of formula (IV) from the compounds of formula (III) according to the method as defined above.
• the invention also relates to a process for the preparation of the compounds of formula (I) from the compounds of formula (IV) according to the method as defined above.
• the compounds of formula R 5 -M are prepared according to conventional methods in organic chemistry from the corresponding halogen derivative Rs-Hal. In general, the reagents
• Grignards are prepared in situ before the arylation reaction and transformed into cuprate in situ, catalytically in the presence of CuCl.
• halogen derivatives of formula R 5 -Hal are known or generally prepared by the action of a chloroamine of formula R ⁇ R 2 N- (CH 2 ) n -Cl with parabromophenol in basic medium.
• Example 1 17-alpha-methyl-ll-beta- (4- (2- (1-piperidinyl) ethoxy) phenyl) -estra-1,3,5 (10) -triene-3,17-beta-diol Stage a: 3, 3-ethylenedioxy-10-alpha-epoxy-estr-9 (11) -ene-17-one. (compound of formula (II))
• Step b d # silylated enol ether 3: 3.3 ethylenedioxy-5,10-alpha-epoxy-17-trimethylsilyloxy-estra-9 (11), 16 (17) -diene.
• N-Butyllithium 1.6 M solution in a mixture of hexanes; 400 ml; 1.06 eq.
• M diisopropylamine
• the silylated enol ether as prepared above (0.60 moles) is diluted with THF (600 ml) and this solution is added for 1 h at around -5 ° C. to the mixture of Grignard reagents and cuprate formed in situ .
• the mixture is stirred for 1 h at 0 ° C., then poured into a two-phase mixture of ammonium chloride (600 g) in water (4 L). Extraction is carried out with dichloromethane. The organic phase is then washed with water and concentrated in vacuo.
• Dichloromethane is replaced by diisopropyl ether at 40-45 ° C at constant volume.
• the expected enone crystallizes, and is filtered at 20-22 ° C and then dried under vacuum at 35-40 ° C. (236 g white solid; yield: 82.3%; (from epoxy 2): C 3 ⁇ H 39 0 3 ; PM: 473.7;

Applications Claiming Priority (3)

Publications (1)

Family

ID=8864249

Family Applications (1)

Country Status (5)

Cited By (1)

Families Citing this family (3)

Family Cites Families (11)

• 2001
  • 2001-06-13 FR FR0107711A patent/FR2826004B1/fr not_active Expired - Fee Related
• 2002
  • 2002-06-12 WO PCT/FR2002/002001 patent/WO2002100880A1/fr active Application Filing
  • 2002-06-12 JP JP2003503646A patent/JP2004534796A/ja active Pending
  • 2002-06-12 US US10/480,618 patent/US7381718B2/en not_active Expired - Lifetime
  • 2002-06-12 EP EP02747527A patent/EP1404701A1/de not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events